These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37221330)

  • 1. Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women.
    Jansen van Vuuren CJ; Lewis L; Harkoo I; Dawood H; Mansoor LE
    AIDS Behav; 2023 Nov; 27(11):3596-3602. PubMed ID: 37221330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
    Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
    J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya.
    Wara NJ; Mvududu R; Marwa MM; Gómez L; Mashele N; Orrell C; Moucheraud C; Kinuthia J; John-Stewart G; Myer L; Hoffman R; Pintye J; Davey DLJ
    J Int AIDS Soc; 2023 May; 26(5):e26088. PubMed ID: 37221983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familiarity and acceptability of long-acting reversible contraception and contraceptive choice.
    Paul R; Huysman BC; Maddipati R; Madden T
    Am J Obstet Gynecol; 2020 Apr; 222(4S):S884.e1-S884.e9. PubMed ID: 31838124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on sexual and reproductive health self-care among women, healthcare providers, and other key informants: a mixed-methods study in South Africa and Zambia.
    Cartwright AF; Velarde M; Beksinska M; Smit J; Kasaro M; Tang JH; Milford C; Maphumulo V; Chinyama M; Chabu E; Mudenda M; Wong C; Fawzy M; Callahan R
    Reprod Health; 2023 Apr; 20(1):65. PubMed ID: 37118835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating end-users' voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe.
    Browne EN; Manenzhe K; Makoni W; Nkomo S; Mahaka I; Ahmed K; Shapley-Quinn MK; Marton T; Luecke E; Johnson L; van der Straten A; Minnis AM
    BMC Womens Health; 2023 Feb; 23(1):58. PubMed ID: 36765358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is long-acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu-Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study.
    Beksinska M; Cartwright AF; Smit J; Kasaro M; Tang JH; Fawzy M; Maphumulo V; Chinyama M; Chabu E; Callahan R
    Contracept X; 2023; 5():100089. PubMed ID: 36718374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.
    Murnane PM; Heffron R; Ronald A; Bukusi EA; Donnell D; Mugo NR; Were E; Mujugira A; Kiarie J; Celum C; Baeten JM;
    AIDS; 2014 Jul; 28(12):1825-30. PubMed ID: 24785951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.
    Hsu JH; Ku SW; Chen TW; Li CW; Huang P; Wu HJ; Bourne A; Strong C
    J Int AIDS Soc; 2023 Sep; 26(9):e26163. PubMed ID: 37675767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting hormonal contraceptives for women.
    Garza-Flores J; Hall PE; Perez-Palacios G
    J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alignment of PrEP use and effective contraceptive use among East African women in HIV serodiscordant partnerships.
    Ngure K; Velloza J; Patel RC; Mugo NR; Bukusi EA; Haberer JE; Odoyo J; Celum C; Baeten JM; Heffron R
    Int J STD AIDS; 2020 Nov; 31(13):1263-1271. PubMed ID: 32998640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study.
    Rael CT; Lentz C; Carballo-Diéguez A; Giguere R; Dolezal C; Feller D; D'Aquila RT; Hope TJ
    J Med Internet Res; 2020 Jul; 22(7):e16904. PubMed ID: 32348277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.
    Balkus JE; Brown ER; Hillier SL; Coletti A; Ramjee G; Mgodi N; Makanani B; Reid C; Martinson F; Soto-Torres L; Abdool Karim SS; Chirenje ZM
    Contraception; 2016 Jan; 93(1):25-31. PubMed ID: 26519646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study.
    Chappell CA; Harkoo I; Szydlo DW; Bunge KE; Singh D; Nakabiito C; Mhlanga F; Kamira B; Piper JM; Balkus JE; Hillier SL;
    Contraception; 2019 Sep; 100(3):214-218. PubMed ID: 31226323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
    Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.